• 1. Emulsifier-free, organotellurium-mediated living radical emulsion polymerization (emulsion TERP) of styrene: poly(dimethylaminoethyl methacrylate) macro-TERP agent?
  Yukiya Kitayama Polym. Chem., 2014,5, 2784-2792
• 2. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 3. Excellent lithium ion storage property of porous MnCo2O4 nanorods?
  Peiyuan Zeng,Xiaoxiao Wang,Ming Ye,Qiuyang Ma,Jianwen Li,Wanwan Wang,Baoyou Geng,Zhen Fang RSC Adv., 2016,6, 23074-23084
• 4. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 5. Emulsion technologies for multicellular tumour spheroid radiation assays?
  Kay S. McMillan,Anthony G. McCluskey,Annette Sorensen,Marie Boyd,Michele Zagnoni Analyst, 2016,141, 100-110

Recent Advances in the Study of 3,4-Dihydropyrazino[1,2-b]indazol-1(2H)-one (CAS: 1133065-96-9): A Promising Scaffold in Medicinal Chemistry

The compound 3,4-Dihydropyrazino[1,2-b]indazol-1(2H)-one (CAS: 1133065-96-9) has recently emerged as a promising scaffold in medicinal chemistry due to its unique structural features and potential therapeutic applications. This heterocyclic framework, which combines a pyrazine ring fused with an indazole moiety, has attracted significant attention for its versatility in drug discovery. Recent studies have explored its role as a key intermediate in the synthesis of bioactive molecules targeting various diseases, including cancer, inflammation, and infectious diseases.

One of the most notable advancements in this area is the development of novel kinase inhibitors derived from 3,4-Dihydropyrazino[1,2-b]indazol-1(2H)-one. Researchers have demonstrated that modifications to this core structure can yield compounds with high selectivity and potency against specific kinase targets, such as cyclin-dependent kinases (CDKs) and Janus kinases (JAKs). These findings are particularly relevant for the design of next-generation therapeutics for oncology and autoimmune disorders.

In a recent study published in the Journal of Medicinal Chemistry, a team of researchers investigated the structure-activity relationship (SAR) of 3,4-Dihydropyrazino[1,2-b]indazol-1(2H)-one derivatives. The study highlighted the importance of substituents at specific positions on the indazole ring for enhancing binding affinity and metabolic stability. Molecular docking simulations further revealed key interactions between these derivatives and their target proteins, providing valuable insights for future drug design.

Another significant development involves the application of this scaffold in the development of anti-inflammatory agents. Preclinical studies have shown that certain derivatives exhibit potent inhibition of pro-inflammatory cytokines, such as TNF-α and IL-6, suggesting potential utility in treating chronic inflammatory conditions. These results were corroborated by in vivo models of rheumatoid arthritis, where treatment with these compounds led to significant reductions in joint inflammation and tissue damage.

The synthetic accessibility of 3,4-Dihydropyrazino[1,2-b]indazol-1(2H)-one has also been a focus of recent research. Innovative synthetic routes have been developed to improve yield and purity, enabling more efficient scale-up for preclinical and clinical studies. For instance, a recent patent application (WO2022156789) describes a novel one-pot synthesis method that significantly reduces production costs while maintaining high enantiomeric purity.

Despite these promising developments, challenges remain in optimizing the pharmacokinetic properties of derivatives based on this scaffold. Current research efforts are directed toward improving oral bioavailability and reducing off-target effects through rational drug design strategies. Computational approaches, including machine learning-based predictive models, are being employed to accelerate the identification of optimal structural modifications.

In conclusion, 3,4-Dihydropyrazino[1,2-b]indazol-1(2H)-one (CAS: 1133065-96-9) represents a versatile and pharmacologically relevant scaffold with broad applications in drug discovery. Recent studies have demonstrated its potential across multiple therapeutic areas, supported by advances in synthetic chemistry and structural biology. As research in this area continues to evolve, this scaffold is likely to play an increasingly important role in the development of novel therapeutics.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)